Prevention and treatment of Clostridium difficile associated diarrhea by reconstitution of the microbiota

Keyphrases

• Antibiotic Therapy 50%
• C. Difficile Toxin 50%
• Cause of Disease 50%
• Clostridium Difficile Infection 100%
• Clostridium Difficile-associated Diarrhea 100%
• Common Infectious Diseases 50%
• Competitive Inhibition 50%
• Developed Countries 50%
• Difficile 100%
• Fecal Microbiota Transplantation 50%
• Fidaxomicin 50%
• Gut Microbiota 100%
• Infection Recurrence 50%
• Metronidazole 50%
• Microbiota 100%
• Monoclonal Antibody 50%
• New Antibiotics 50%
• New Drugs 50%
• New Therapies 50%
• Nontoxigenic Strains 50%
• Nosocomial Diarrhea 50%
• Reconstitution 100%
• Recurrence Rate 50%
• Therapeutic Focus 50%
• Therapeutic Proteins 50%
• Vancomycin 50%

Pharmacology, Toxicology and Pharmaceutical Science

• Antibiotic Agent 33%
• Antibiotic Therapy 33%
• Clostridium Difficile Infection 100%
• Diarrhea 33%
• Feces microflora 33%
• Fidaxomicin 33%
• Infection 33%
• Intestine Flora 66%
• Metronidazole 33%
• Microflora 100%
• Monoclonal Antibody 33%
• Recurrence Risk 33%
• Recurrent Disease 66%
• Vancomycin 33%

Medicine and Dentistry

• Antibiotic Therapy 33%
• Antibiotics 33%
• Clostridium Difficile Infection 100%
• Competitive Inhibition 33%
• Diarrhea 33%
• Fecal Microbiota Transplantation 33%
• Fidaxomicin 33%
• Gut Microbiota 66%
• Infection 33%
• Metronidazole 33%
• Monoclonal Antibody 33%
• Recurrence Risk 33%
• Recurrent Disease 66%
• Vancomycin 33%